Blake Borgeson is Director at RECURSION PHARMACEUTICALS, INC. (RXRX). They have made 29 open-market trades across 1 company since 2021, most recently 2026-10-06.
CIK 0001856094
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 29 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| RXRX | 6,108,287 | $21.1M |
Shares reported on the most recent Form 4, priced at the 2026-10-07 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| RXRX | SELL · 10b5-1 | 2026-10-06 | 2026-10-07 | $4.84 | $242K | — | — | — |
| RXRX | SELL · 10b5-1 | 2026-09-01 | 2026-09-02 | $3.34 | $100K | -5.8% | +20.2% | — |
| RXRX | SELL · 10b5-1 | 2026-08-04 | 2026-08-06 | $3.25 | $98K | -4.6% | +5.7% | — |
| RXRX | SELL · 10b5-1 | 2026-07-07 | 2026-07-09 | $3.96 | $159K | -19.1% | -13.2% | +12.7% |
| RXRX | SELL · 10b5-1 | 2026-06-02 | 2026-06-04 | $3.68 | $110K | -12.0% | +9.1% | -6.9% |
| RXRX | SELL · 10b5-1 | 2026-05-05 | 2026-05-07 | $3.52 | $106K | -13.5% | +0.3% | -3.8% |
| RXRX | SELL · 10b5-1 | 2026-04-07 | 2026-04-08 | $3.10 | $93K | +10.8% | -0.2% | +15.6% |
| RXRX | SELL | 2026-03-03 | 2026-03-04 | $3.46 | $588K | -4.5% | -11.3% | +1.7% |
| RXRX | SELL · 10b5-1 | 2026-02-03 | 2026-02-06 | $4.20 | $924K | -5.8% | -11.1% | -17.2% |
| RXRX | SELL · 10b5-1 | 2026-01-06 | 2026-01-08 | $4.36 | $959K | -3.6% | -16.7% | -29.1% |
| RXRX | SELL · 10b5-1 | 2025-12-02 | 2025-12-04 | $4.37 | $961K | -13.8% | -10.3% | -25.3% |
| RXRX | SELL · 10b5-1 | 2024-11-12 | 2024-11-14 | $7.64 | $175K | -14.5% | +8.0% | +21.0% |
| RXRX | SELL · 10b5-1 | 2024-10-29 | 2024-10-31 | $6.72 | $154K | +19.2% | +19.2% | +12.6% |
| RXRX | SELL · 10b5-1 | 2024-10-15 | 2024-10-17 | $6.67 | $153K | +2.6% | -7.2% | -2.3% |
| RXRX | SELL · 10b5-1 | 2024-10-01 | 2024-10-03 | $6.22 | $142K | +8.5% | +8.0% | +17.2% |
| RXRX | SELL · 10b5-1 | 2024-09-17 | 2024-09-19 | $6.84 | $157K | -10.1% | -1.5% | -9.4% |
| RXRX | SELL · 10b5-1 | 2024-09-03 | 2024-09-05 | $6.27 | $144K | +9.7% | +0.3% | +15.7% |
| RXRX | SELL · 10b5-1 | 2024-08-20 | 2024-08-22 | $7.12 | $163K | -18.2% | -10.6% | -19.0% |
| RXRX | SELL · 10b5-1 | 2024-08-06 | 2024-08-08 | $6.82 | $156K | +4.8% | -10.4% | +2.0% |
| RXRX | SELL · 10b5-1 | 2024-07-23 | 2024-07-25 | $8.48 | $194K | -18.7% | -4.4% | -23.3% |
| RXRX | SELL · 10b5-1 | 2024-07-09 | 2024-07-11 | $7.32 | $168K | +10.1% | -22.6% | -21.1% |
| RXRX | SELL · 10b5-1 | 2024-06-25 | 2024-06-27 | $9.51 | $218K | -4.5% | +8.2% | -9.0% |
| RXRX | SELL · 10b5-1 | 2024-06-11 | 2024-06-13 | $8.45 | $193K | -5.2% | -11.3% | -30.2% |
| RXRX | SELL · 10b5-1 | 2024-05-28 | 2024-05-30 | $9.17 | $210K | -3.9% | -16.5% | -17.5% |
| RXRX | SELL · 10b5-1 | 2024-05-14 | 2024-05-16 | $10.12 | $406K | -9.7% | -1.4% | -33.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.